Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.

The approval is supported by data from the phase 3 LITESPARK-011 trial.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

A recap of the FDA submissions and regulatory decisions in urology from September 2026.